BofA lowered the firm’s price target on Ultragenyx (RARE) to $80 from $83 and keeps a Buy rating on the shares. The firm updated models in smid-cap biotech as part of a Q1 earnings preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx price target raised to $117 from $104 at JPMorgan
- Rezolute appoints Erik Harris to board of directors
- Ultragenyx price target lowered to $115 from $140 at Piper Sandler
- Ultragenyx assumed with an Overweight at Morgan Stanley
- Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Growth Potential and Robust Pipeline